Genitourinary Cancers Symposium

Researchers Probe Concurrent Timing of ADT Use Drop and Medicare Reimbursement Policy Change

Rosemary Frei, MSc

May 2010, Vol 1, No 1 - Genitourinary Cancers Symposium

San Francisco, CA—By mining the Surveillance, Epidemiology and End Results-Medicare Database, researchers have documented a significant de cline in nonevidence-based use of androgen deprivation therapy (ADT) for prostate cancer between 2003 and 2005. This coincides with a significant drop in Medicare reimbursement in 2004 for the form of [ Read More ]

Better Diagnostic Accuracy Through More Testing? Not Necessarily When It Comes to Bladder Cancer

Rosemary Frei, MSc

May 2010, Vol 1, No 1 - Genitourinary Cancers Symposium

San Francisco, CA—A new study challenges the notion that more testing leads to greater accuracy in detection of non–muscle-invasive bladder cancer (NMIBC). Results presented at the ASCO 2010 Genitourinary Cancers Symposium indicate that cystoscopy alone costs $7692 per tumor detected and has a low false-positive rate. Adding cytology, nuclear [ Read More ]